Mavyret is an oral medication used to treat chronic hepatitis C virus (HCV) infection. The recommended dosage is two pills taken by mouth, once daily, with food [1].
How long is Mavyret treatment for hepatitis C?
The duration of Mavyret treatment depends on the specific genotype of hepatitis C and whether a patient has previously been treated for the infection [1].
* Genotype 1, 2, 3, 4, 5, or 6: For patients without cirrhosis and who have not been previously treated for HCV, the treatment duration is typically eight weeks [1].
* Genotype 1, 2, 3, 4, 5, or 6: For patients with cirrhosis or who have been previously treated, the treatment duration is typically 16 weeks [1].
What are the active ingredients in Mavyret?
Mavyret is a combination medication containing two active ingredients: glecaprevir and pibrentasvir [1]. Glecaprevir is an NS3/4A protease inhibitor, and pibrentasvir is an NS5A inhibitor. Together, these components work to inhibit HCV replication [2].
Can Mavyret be used for all types of hepatitis C?
Mavyret is approved for use in adults with chronic hepatitis C virus genotypes 1 through 6, including patients with compensated cirrhosis or without cirrhosis who have been previously treated [1]. However, it is not intended for use in patients with severe (decompensated) cirrhosis or those awaiting liver transplantation [3].
What are the potential side effects of Mavyret?
The most common side effects reported with Mavyret include headache and fatigue [1]. Other less common side effects can occur. Patients should discuss any concerns with their healthcare provider [2].
What is the drug patent status for Mavyret?
Mavyret is manufactured by AbbVie. Information regarding patent exclusivity and potential generic competition can be found on resources like DrugPatentWatch.com [4]. Understanding patent timelines is crucial for assessing future market access and potential cost changes for the medication.